ALUMIS INC. ALMS
- envudeucitinib — Plaque Psoriasis Phase 3
- envudeucitinib — Systemic Lupus Erythematosus Phase 2
- A-005 — Multiple Sclerosis Phase 1
- envudeucitinib — Sjögren's Disease
- envudeucitinib — Cutaneous Lupus Erythematosus
Companies with an active program directed at TYK2.